In­cyte says un­der-the-radar JAK in­hibitor clears a high bar for skin dis­or­der

In­cyte — the com­pa­ny be­hind Jakafi and Olu­mi­ant — wants to put a third JAK in­hibitor on the map.

Pre­sent­ing at the Eu­ro­pean Hidradeni­tis Sup­pu­ra­ti­va Foun­da­tion con­fer­ence, the biotech high­light­ed long-term da­ta from a Phase II tri­al test­ing povorci­tinib as a treat­ment for hidradeni­tis sup­pu­ra­ti­va (HS), a skin con­di­tion char­ac­ter­ized by painful nod­ules and ab­scess­es.

If the re­sults hold up in Phase III, the drug may “es­tab­lish a new high wa­ter mark for ef­fi­ca­cy,” Cowen an­a­lyst Marc Frahm wrote in a note, even as it goes against Ab­b­Vie’s Hu­mi­ra and No­var­tis’ Cosen­tyx.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER